Cypress Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Cypress Capital’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-173	Closed	-$10.3K	–	115
2024 Q2	$10.3K	Buy	+173	New	+$9.57K	﹤0.01%	187

Other funds holding BIB

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

WWM

Westwood Wealth Management Los Angeles, California $255M AUM 54.97% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CCWM

Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

Cypress Capital's BIB Position: Q3 2024 in Review

Cypress Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2024, closing a stake of 173 shares — an estimated $10.3K sold.

Cypress Capital first reported a position in BIB in Q2 2024 and held it in 1 quarter. The position peaked at $10.3K in Q2 2024. 21 funds tracked by Wall St. Rank hold BIB as of Q3 2024.

Cypress Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 173 ProShares Ultra NASDAQ Biotechnology shares in Q3 2024, an estimated $10.3K.
Cypress Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2024 and held it in 1 quarter.
Cypress Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $10.3K in Q2 2024.
21 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.